[November 27, 2015] |
|
Research and Markets: Rotavirus Infections Therapeutic Development - Pipeline Review & Analysis, H2 2015
Research and Markets (http://www.researchandmarkets.com/research/68dl3q/rotavirus)
has announced the addition of the "Rotavirus
Infections - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic
development for Rotavirus Infections, complete with comparative analysis
at various stages, therapeutics assessment by drug target, mechanism of
action (MoA), route of administration (RoA) and molecule type, along
with latest updates, and featured news and press releases. It also
reviews key players involved in the therapeutic development for
Rotavirus Infections and special features on late-stage and discontinued
projects.
Key Topics Covered:
-
The report provides a snapshot of the global therapeutic landscape of
Rotavirus Infections
-
The report reviews key pipeline products under drug profile section
which includes, product description, MoA and R&D brief, licensing and
collaboration details & other developmental activities
-
The report reviews key players involved in the therapeutics
development for Rotavirus Infections and enlists all their major and
minor projects
-
The report summarizes all the dorant and discontinued pipeline
projects
-
A review of the Rotavirus Infections products under development by
companies and universities/research institutes based on information
derived from company and industry-specific sources
-
Pipeline products coverage based on various stages of development
ranging from pre-registration till discovery and undisclosed stages
-
A detailed assessment of monotherapy and combination therapy pipeline
projects
-
Coverage of the Rotavirus Infections pipeline on the basis of target,
MoA, route of administration and molecule type
-
Latest news and deals relating related to pipeline products
Benefits of this Report:
-
Provides strategically significant competitor information, analysis,
and insights to formulate effective R&D development strategies
-
Identify emerging players with potentially strong product portfolio
and create effective counter-strategies to gain competitive advantage
-
Develop strategic initiatives by understanding the focus areas of
leading companies
-
Identify and understand important and diverse types of therapeutics
under development for Rotavirus Infections
-
Plan mergers and acquisitions effectively by identifying key players
of the most promising pipeline
-
Devise corrective measures for pipeline projects by understanding
Rotavirus Infections pipeline depth and focus of Indication
therapeutics
-
Develop and design in-licensing and out-licensing strategies by
identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope
-
Modify the therapeutic portfolio by identifying discontinued projects
and understanding the factors that drove them from pipeline
Companies Mentioned:
-
Beijing Minhai Biotechnology Co., Ltd
-
Biological E. Limited
-
CureVac GmbH
-
Medicago Inc.
-
Nanotherapeutics, Inc.
-
SEEK Group
-
Serum Institute of India Limited
-
Shantha Biotechnics Limited
-
Sinovac Biotech Ltd.
-
Takeda Pharmaceutical Company Limited
For more information visit http://www.researchandmarkets.com/research/68dl3q/rotavirus
View source version on businesswire.com: http://www.businesswire.com/news/home/20151127005413/en/
[ Back To TMCnet.com's Homepage ]
|